| Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection (NCT05517811) | University of Colorado, Denver | 2022-06-26 |
| Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies (NCT05462314) | Viome | 2022-03-29 |
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). (NCT04566133) | National Cancer Institute (NCI) | 2022-02-15 |
| Neoadjuvant Therapy in Biliary Adenocarcinoma (NCT04480190) | Jordan Kharofa | 2021-02-04 |
| Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (NCT04644068) | AstraZeneca | 2020-11-12 |
| Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy (NCT04517448) | Centre Hospitalier de la côte Basque | 2020-10-16 |
| A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer (NCT02908451) | AbGenomics B.V Taiwan Branch | 2017-04-24 |
| Pembrolizumab and GM-CSF in Biliary Cancer (NCT02703714) | Robin Kate Kelley | 2016-05-06 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) (NCT02628067) | Merck Sharp & Dohme LLC | 2015-12-18 |
| Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures. (NCT02930252) | Azienda USL 1 Imperiese | 2014-12-01 |
| My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (NCT02091141) | Genentech, Inc. | 2014-04-14 |
| Preoperative Nutritional Support in Malnutritional Cancer Patients (NCT02626195) | National Cancer Center, Korea | 2013-10-01 |
| Tremelimumab With Chemoembolization or Ablation for Liver Cancer (NCT01853618) | National Cancer Institute (NCI) | 2013-05-02 |
| Postoperative Oral Nutritional Supplementation After Major Gastrointestinal Surgery (NCT01838109) | Seoul National University Hospital | 2013-04-01 |
| Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer (NCT01773785) | Spectrum Pharmaceuticals, Inc | 2013-04-01 |
| GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer (NCT01859728) | Hospital de Cancer de Barretos - Fundacao Pio XII | 2013-01-01 |
| A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers (NCT01661114) | University of Michigan Rogel Cancer Center | 2011-07-01 |
| Perception Prognosis, Goals of Treatment, and Communication (NCT01401894) | Massachusetts General Hospital | 2010-10-01 |
| IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread (NCT01099631) | Masonic Cancer Center, University of Minnesota | 2010-04-01 |
| A Study of Patients Receiving High-Dose Rate Brachytherapy (NCT00924027) | National Cancer Institute (NCI) | 2009-04-14 |
| Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma (NCT00948935) | Abramson Cancer Center at Penn Medicine | 2009-04-01 |
| Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers (NCT00626158) | University of California, San Francisco | 2008-02-01 |
| Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors (NCT00551096) | University of Colorado, Denver | 2007-10-01 |
| GTX Regimen for Biliary Cancers (NCT00868998) | Columbia University | 2005-08-01 |